Insulet saw its IBD SmartSelect Composite Rating jump to 98 Monday, up from 93 the day before.
Lean How — And When — To Sell Stocks
The new score indicates the company is now outperforming 98% of all stocks in terms of the most important fundamental and technical stock-picking criteria.
Insulet is now out of buy range after breaking out from a 289.46 buy point in a consolidation.
The stock sports a 94 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 94% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
The company posted 67% earnings growth for Q1. Sales growth increased 29%, up from 17% in the prior quarter. That marks one quarter of rising revenue increases.
Insulet holds the No. 3 rank among its peers in the Medical-Products industry group. Penumbra is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
